Logo image
Hepatitis C Virus Infection: A New Era
Book chapter

Hepatitis C Virus Infection: A New Era

Santiago J. Munoz, Kenneth D. Rothstein and Alexandra L. Gibas
Contemporary Liver Transplantation, pp 247-254
01 Jan 2017

Abstract

Gastroenterology & Hepatology Life Sciences & Biomedicine Science & Technology Transplantation
Rapid and dramatic advances in development of the modern generation of direct antiviral agents specific for hepatitis C have occurred over the last 3 years. In this chapter, we discuss the applications of the new antiviral agents to patients with hepatitis C infection relevant to liver transplantation, namely, those with compensated and decompensated cirrhosis, patients with hepatocellular carcinoma (HCC) related to HCV, and in liver transplant recipients with recurrent HCV. The limits of applicability of the new direct antiviral agents (DAAs) are reviewed, as well as the new issues raised by the high rates of HCV cure. The global impact of high cure rates of HCV has not yet been fully appreciated. Access to the new antiviral agents and diagnosing the large numbers of patients currently unaware of this infection are clearly now the major challenges, rather than discovering new agents to optimizing cure rates. Liver transplantation for HCV and HCV-related HCC is likely to remain at current levels for the rest of the decade, but recipients and allografts are likely to enjoy a much longer useful life following HCV eradication with DAAs.

Metrics

12 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Gastroenterology & Hepatology
Transplantation
Logo image